Building Medical Supply Chain Resilience through a U.S. Manufacturing Reserve and Digital Stockpile
Summary
To prevent another medical supply chain breakdown like the one experienced during the COVID-19 pandemic, the Federal Government must create an emergency response plan to activate domestic, local medical supply manufacturing. A national network of small-to-mid-size manufacturers and prototyping labs — a U.S. Prototyping and Manufacturing Reserve — should be formalized and incentivized to act as first responders for emergency innovation and medical supply manufacturing needs.
To properly equip the Reserve, the Federal Government should build a comprehensive library of open source medical and emergency supply “blueprints” — a U.S. Digital Stockpile — that consists of manufacturing requirements to enable distributed local emergency production. Combined, these new national security resources will facilitate rapid local response to both regional disasters and international supply chain disruptions.
By providing essential funding mechanisms, the Bioeconomy Finance Program will reduce the risks inherent in biotechnology innovation, encouraging more private sector investment.
While the U.S. has made significant advancements and remained a global leader in biotechnology over the past decade, the next four years will be critical in determining whether it can sustain that leadership.
It’s paramount to balance both innovation capabilities and risk as we work towards ensuring that the U.S. bioeconomy is a priority area for both the Nation and for National Security.
The Federation of American Scientists supports the National Security Commission on Emerging Biotechnology’s Final Report and the Recommendations contained within it.